Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study

Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up

Journal of Interferon Research ◽

10.1089/jir.1993.13.333 ◽

1993 ◽

Vol 13 (5) ◽

pp. 333-340 ◽

Cited By ~ 69

Author(s):

R.L. KNOBLER ◽

J.I. GREENSTEIN ◽

K.P. JOHNSON ◽

F.D. LUBLIN ◽

H.S. PANITCH ◽

...

Keyword(s):

Multiple Sclerosis ◽

Pilot Study ◽

Human Interferon ◽

Study Analysis ◽

Interferon Β ◽

Relapsing Remitting ◽

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study

BMC Neurology ◽

10.1186/1471-2377-11-125 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 8

Author(s):

Stefano Bastianello ◽

◽

Elisabetta Giugni ◽

Maria Pia Amato ◽

Maria-Rosalia Tola ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Multiple Sclerosis ◽

Cognitive Impairment ◽

Magnetic Resonance ◽

Resonance Imaging ◽

Interferon Β ◽

Relapsing Remitting ◽

Disabled Patients ◽

Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)

Quality of Life Research ◽

10.1007/s11136-011-0021-6 ◽

2011 ◽

Vol 21 (7) ◽

pp. 1111-1121 ◽

Cited By ~ 5

Author(s):

Francesco Patti ◽

Maria Pia Amato ◽

Maria Trojano ◽

Stefano Bastianello ◽

Maria Rosalia Tola ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cognitive Impairment ◽

Social Functioning ◽

Interferon Β ◽

Longitudinal Changes ◽

Relapsing Remitting ◽

Disabled Patients ◽

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

The incidence of cognitive impairment among Hungarian relapsing-remitting multiple sclerosis patients

10.26226/morressier.59a3e8b4d462b8028d894334 ◽

2017 ◽

Author(s):

Dániel Sandi

Keyword(s):

Multiple Sclerosis ◽

Cognitive Impairment ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Contrasting responses to interferon β-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

Annals of Neurology ◽

10.1002/1531-8249(200009)48:3<313::aid-ana5>3.0.co;2-9 ◽

2000 ◽

Vol 48 (3) ◽

pp. 313-322 ◽

Cited By ~ 28

Author(s):

A. H. H. Van Boxel-Dezaire ◽

S. C. J. Van Trigt-Hoff ◽

J. Killestein ◽

H. M. Schrijver ◽

J. C. Van Houwelingen ◽

...

Keyword(s):

Multiple Sclerosis ◽

Messenger Rna ◽

Interferon Β ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Efficacy Of Treatment

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial

Frontiers in Behavioral Neuroscience ◽

10.3389/fnbeh.2016.00028 ◽

2016 ◽

Vol 10 ◽

Cited By ~ 11

Author(s):

Flavia Mattioli ◽

Fabio Bellomi ◽

Chiara Stampatori ◽

Leandro Provinciali ◽

Laura Compagnucci ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Cognitive Training ◽

Domain Specific ◽

Relapsing Remitting ◽

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286420968357 ◽

2020 ◽

Vol 13 ◽

pp. 175628642096835

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Safety And Efficacy ◽

Delayed Release ◽

Relapsing Remitting ◽

Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study)

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2018.10.086 ◽

2018 ◽

Vol 26 ◽

pp. 258 ◽

Cited By ~ 1

Author(s):

R. Alroughani ◽

B.A. Singer ◽

S. Broadley ◽

S. Eichau ◽

H. Hartung ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Brain Volume ◽

Volume Loss ◽

Brain Volume Loss ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Corpus callosum function in verbal dichotic listening: Inferences from a longitudinal follow-up of Relapsing-Remitting Multiple Sclerosis patients

Brain and Language ◽

10.1016/j.bandl.2009.03.006 ◽

2009 ◽

Vol 110 (2) ◽

pp. 101-105 ◽

Cited By ~ 18

Author(s):

Marien Gadea ◽

Luis Marti-Bonmatí ◽

Estanislao Arana ◽

Raul Espert ◽

Alicia Salvador ◽

...

Keyword(s):

Multiple Sclerosis ◽

Corpus Callosum ◽

Dichotic Listening ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽